Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19693] to PI 3 Kinase catalytic subunit alpha/PIK3CA - BSA and Azide free
- Suitable for: IP, WB
- Knockout validated
- Reacts with: Mouse, Rat
Product nameAnti-PI 3 Kinase catalytic subunit alpha/PIK3CA antibody [EPR19693] - BSA and Azide free
See all PI 3 Kinase catalytic subunit alpha/PIK3CA primary antibodies
DescriptionRabbit monoclonal [EPR19693] to PI 3 Kinase catalytic subunit alpha/PIK3CA - BSA and Azide free
Tested applicationsSuitable for: IP, WBmore details
Species reactivityReacts with: Mouse, Rat
Recombinant fragment aa 1-350. The exact sequence is proprietary.
Database link: P42337
- WB: F9 and M1 whole cell lysates; Mouse hypothalamus and fetal brain lysates; P0 Rat brain lysate. IP: Mouse hypothalamus lysate.
Ab223532 is the carrier-free version of ab183957. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
ab223532 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferpH: 7.2
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab223532 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Detects a band of approximately 110 kDa (predicted molecular weight: 124 kDa).|
FunctionPhosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.
Involvement in diseaseDefects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].
Defects in PIK3CA are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in PIK3CA are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550].
Defects in PIK3CA are a cause of keratosis seborrheic (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
Sequence similaritiesBelongs to the PI3/PI4-kinase family.
Contains 1 C2 domain.
Contains 1 PI3K/PI4K domain.
- Information by UniProt
- 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha antibody
- 5-bisphosphate 3-kinase catalytic subunit alpha isoform antibody
- caPI3K antibody
This WB data was generated using the same anti-PI 3 Kinase catalytic subunit alpha/PIK3CA antibody clone [EPR19693] in a different buffer formulation (cat# ab183957).
Lane 1: Wild type HAP1 whole cell lysate (20 µg)
Lane 2: PI 3 Kinase catalytic subunit alpha/PIK3CA knockout HAP1 whole cell lysate (20 µg)
Lane 3: HeLa whole cell lysate (20 µg)
Lane 4: Jurkat whole cell lysate (20 µg)
ab183957 was shown to recognize PI 3 Kinase catalytic subunit alpha/PIK3CA in wild type cells as signal was lost at the expected MW in PI 3 Kinase catalytic subunit alpha/PIK3CA knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and PI 3 Kinase catalytic subunit alpha/PIK3CA knockout samples were subjected to SDS-PAGE. ab183957 and ab9484 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
This IP data was generated using the same anti-PI 3 Kinase catalytic sunbunit alpha antibody clone [EPR19693] in a different buffer formulation (cat# ab183957).
PI 3 Kinase catalytic subunit alpha was immunoprecipitated from 0.35 mg of mouse hypothalamus lysate with ab183957 at 1/30 dilution.
Western blot was performed from the immunoprecipitate using ab183957 at 1/500 dilution.
VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: Mouse hypothalamus lysate, 10µg (Input).
Lane 2: ab183957 IP in mouse hypothalamus lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
ab223532 has not yet been referenced specifically in any publications.